Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
Saskia Räuber(Düsseldorf University Hospital), David Kremer(Heinrich Heine University Düsseldorf), Philipp Albrecht(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Melanie Korsen(Heinrich Heine University Düsseldorf), Christina B. Schroeter(University of Münster), Niklas Huntemann(Düsseldorf University Hospital), Sven G. Meuth(University Hospital Münster), Marius Ringelstein(Medizinische Hochschule Hannover), Tristan Kölsche(Heinrich Heine University Düsseldorf), Liesa Regner-Nelke(Heinrich Heine University Düsseldorf), Orhan Aktaş(Heinrich Heine University Düsseldorf), Tobias Ruck(BG University Hospital Bergmannsheil Bochum), Moritz Förster(Heinrich Heine University Düsseldorf), Christopher Nelke(Heinrich Heine University Düsseldorf), Benedikt Plaack(Heinrich Heine University Düsseldorf), Hans‐Peter Hartung(The University of Sydney), Alice Willison(Düsseldorf University Hospital), Nico Melzer(Düsseldorf University Hospital), Michael Barnett(The University of Sydney), Kristin S. Golombeck(University of Münster), Leoni Rolfes(University Hospital Münster), Julia Schüller(Heinrich Heine University Düsseldorf)
Cited by 9
Related Papers
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k